Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

EULAR 2012: Does Arthritis Start in the Gut?

Thomas R. Collins  |  Issue: August 2012  |  August 8, 2012

BERLIN—Interleukin (IL) 23 originating in the gut is a driver of joint inflammation and enthesitis, according to researchers who induced inflammation in mice with overexpression of the cytokine.

The inflammation is a function of IL-23 overproduction and a hypersensitivity of IL-23 at the joints that become inflamed, Jonathan Sherlock, PhD, a researcher at Merck Research Laboratories in Palo Alto, Calif., said here at the European League Against Rheumatism (EULAR) 2012 Annual European Congress of Rheumatology, held June 6–9.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Our idea is that the gut is producing inflammatory cytokines that circulate and connect with the joint, and we propose that there are tissue resident cells in the joint to account for this,” Dr. Sherlock said during a session highlighting bacteria and autoimmune responses relevant to rheumatology.

The IL-23 findings bring new insight to the link between gut inflammation and joint disease.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“We proposed to look at the enthesis because this is the real focal center of pathology in spondylarthropathy, so it’s different from rheumatoid arthritis,” Dr. Sherlock said.

The prominence of IL-23 can be explained by the misfolding of HLA B27 antigen—which gives rise to IL-23 production—and by the presence of the IL-23 receptor polymorphisms present in joint tissue, Dr. Sherlock suggested. “Either overt inflammatory bowel disease or subclinical ileitis in spondylarthropathy, or perhaps the mucosal infections associated with reactive arthritis, are causing production of IL-23” with the misfolding of HLA B27, he said. These cytokines can circulate and act on tissue resident cells.

Researchers overexpressed IL-23 in adult mice. Enthesitis followed, and, after long-term IL-23 exposure, “extremely destructive arthritis” developed, Dr. Sherlock said.

The development of disease was unaffected even after tumor necrosis factor and IL-6 were blocked, and after CD4 cells were depleted, suggesting that IL-23 is the real driver.

“We propose, therefore, that IL-23 is a unifying factor in spondylarthropathy,” Dr. Sherlock said.

Too Few Bacteria Lead to Problems

Another presentation highlighted the key role of IL-10 in maintaining tolerance to harmless bacteria within the gut—the lack of which can lead to inflammatory bowel disease (IBD), which has genetic links to rheumatoid arthritis and other disorders.

Janneke Samsom, PhD, of the department of pediatric gastroenterology at the Erasmus Medical Center in Rotterdam, the Netherlands, said there has been great progress in recent years in understanding the role of IL-10 in IBD, first in mice and more recently in human patients.

The use of germ-free mice has allowed researchers to see the way in which particular bacteria affect the immune response—and it’s been observed that different bacteria use different mechanisms to achieve the same effect.

Page: 1 2 3 | Single Page
Share: 

Filed under:Axial SpondyloarthritisConditionsEULAR/OtherMeeting ReportsResearch Rheum Tagged with:EULARgut microbiomeInternationalReactive arthritisResearch

Related Articles

    Reactive Arthritis

    October 1, 2010

    Back to the Future

    Watch Those Eyes

    December 1, 2007

    What you need to know about Uveitis in Rheumatic Diseases

    The Microbiome

    November 1, 2011

    A voyage to (our inner) Lilliput

    Treatment Patterns and Trends for Spondylarthropathies

    April 6, 2012

    Methotrexate is a commonly used disease-modifying antirheumatic drug (DMARD) for treating patients with psoriatic arthritis (PsA). However, is it truly as effective as many think it is? That’s the question raised during the session “Spondylarthropathies: Recent Insights,” which took place at the 2011 ACR/ARHP Annual Scientific Meeting in November.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences